Clinical Trial Update: 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating 18F-DOPA PET imaging for biodistribution and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Glioma
• Congenital Hyperinsulinism
• Neuroblastoma
• Neuroendocrine Tumors
• Parkinson Disease

Drugs mentioned

• 18F-DOPA (fluorodopa)

Snippet

Sponsor: University of Alberta | Conditions: Congenital Hyperinsulinism, Neuroblastoma | Phase 3 | Status: COMPLETED